The Swedish-UK pharmaceutical company AstraZeneca has established a scientific review board to assess requests for patient data from clinical trials.
In an announcement on 19 March, AstraZeneca said that the board has been created to adhere to the European Medicines Agency’s clinical trials regulation, as well as the European Federation of Pharmaceutical Industries and Associations policy.
The board will consider all external requests for access to data from AstraZeneca trials, and assess both the “scientific validity" as well as "how provision of the information may enhance scientific understanding and patient care”, the company states. The board has the option to grant conditional approvals or provide suggestions on how to resubmit requests, as well as accepting or rejecting submissions, states AstraZeneca.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.